Orphan Drug Credits Make It onto Short-Term US Government Spending Bill

As a government shutdown looms large in US politics, certain pharma favorites have made it into a short-term continuing resolution. Key among these is the DeLauro bill, which includes nearly $7 million in funding for rare diseases and orphan drugs research. This program is a long-standing provision, funding work in rare diseases since 1983.

According to Zachary Brennan, “Another $5.7 million (about $500,000 more than last year) would be authorized, if the DeLauro bill passes, for the reauthorization of the Best Pharmaceuticals for Children program, which incentivizes sponsors with additional marketing exclusivity to complete pediatric clinical studies. As of early June, the FDA issued more than 500 written requests for such pediatric trials.”

To read more, click here.

(Source: Endpoints News, December 13^th, 2022)